Winston Pharmaceuticals, Inc.
WPHM
$0.00
$0.000.00%
OTC PK
| 03/31/2010 | 12/31/2009 | 09/30/2009 | 06/30/2009 | 03/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -6.85% | -1.91% | 4,979.71% | 1,715.92% | 325.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.85% | -1.91% | 4,979.71% | 1,715.92% | 325.53% |
| Cost of Revenue | -40.24% | -60.03% | -4.07% | -42.89% | -45.01% |
| Gross Profit | 95.34% | 98.62% | 61.31% | 77.93% | 77.44% |
| SG&A Expenses | -22.49% | -27.88% | -9.39% | 4.64% | 27.15% |
| Depreciation & Amortization | -8.70% | -12.00% | -12.00% | 15.00% | 21.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.05% | -44.89% | -6.52% | -28.56% | -22.23% |
| Operating Income | 41.48% | 56.41% | 37.25% | 52.69% | 42.49% |
| Income Before Tax | 40.84% | 55.65% | 36.61% | 57.37% | 41.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.84% | 55.65% | 36.61% | 57.37% | 41.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.84% | 55.65% | 36.61% | 57.37% | 41.48% |
| EBIT | 41.48% | 56.41% | 37.25% | 52.69% | 42.49% |
| EBITDA | 41.57% | 56.49% | 37.30% | 52.78% | 42.58% |
| EPS Basic | 57.45% | 68.70% | 40.67% | 59.56% | 44.05% |
| Normalized Basic EPS | 57.95% | 68.75% | 41.22% | 54.71% | 43.95% |
| EPS Diluted | 57.45% | 68.70% | 40.67% | 59.56% | 44.05% |
| Normalized Diluted EPS | 57.95% | 68.75% | 41.22% | 54.71% | 43.95% |
| Average Basic Shares Outstanding | 39.96% | 40.75% | 7.08% | 4.98% | 4.72% |
| Average Diluted Shares Outstanding | 39.96% | 40.75% | 7.08% | 4.98% | 4.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |